The drug, inclosing (ponatinib), was predictable to be permitted on March 27, 2013, but as there is no alternative treatment that currently exists for the two unusual blood and marrow diseases, the FDA prioritized its appraisal.
The drug works in the middle of leukemia patients who don't respond to treatment starting a class of drugs called tyrosine kinase inhibitors (TKIs). It workings by blocking proteins that reason cancerous body cells to develop. Sometimes the cancerous cells can expand a mutation called T315I which makes them opposed to to TKIs; Inclosing is efficient at targeting these cells.
The drug works in the middle of leukemia patients who don't respond to treatment starting a class of drugs called tyrosine kinase inhibitors (TKIs). It workings by blocking proteins that reason cancerous body cells to develop. Sometimes the cancerous cells can expand a mutation called T315I which makes them opposed to to TKIs; Inclosing is efficient at targeting these cells.
No comments:
Post a Comment